Obesity Society annual meeting. Oct. 3
Onyx Pharmaceuticals ( ONXX) v. Bayer flurosorafenib litigation gets underway. Oct. 5
Research abstracts for the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting made available. Oct. 6
"Cancer Immunotherapy: A Long-Awaited Reality" conference, sponsored by MD Becker Partners. Oct. 11-15
American Society for Human Genetics (ASHG) meeting. Oct. 13
Rigel Pharmaceuticals ( RIGL) investor/analyst meeting: Asthma strategy and pipeline. Oct. 19-21
ECTRIMS annual meeting. Key data presentations include Teva's ( TEVA) laquinimod and Biogen Idec's ( BIIB) BG-12. Oct. 20-23
Infectious Disease Society of America (IDSA) meeting. Dynavax Technologies ( DVAX) Heplisav Hepatitis B data to be presented. Oct 22-25
American Academy of Opthalmology (AAO) meeting. Oct. 24
Amgen ( AMGN) third-quarter earnings. Oct. 28
FDA approval decision for Pacira Pharmaceuticals' ( PCRX) Exparel for post-surgical pain management.
FDA approval decision date for Bristol-Myers Squibb ( BMY) and AstraZeneca's ( AZN) dapagliflozin for diabetes. An FDA advisory panel on July 19 voted to recommend against approval. Biotech events expected before the end of September:
Biogen Idec: Top-line results of a phase III study of the multiple sclerosis drug BG-12 compared against Teva's Copaxone.
Exelixis ( EXEL): Top-line results of phase III study of cabozantinib in medullary thyroid cancer. Sources: TheStreet research, company announcements, BioMedTracker --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.